Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation With [<sup>18</sup>F] Fluorothymidine Positron Emission Tomography: A Pilot Study
391
Zitationen
11
Autoren
2007
Jahr
Abstract
FLT-PET as an imaging biomarker seems to be predictive of overall survival in bevacizumab and irinotecan treatment of recurrent gliomas. Whether FLT-PET performed as early as 1 to 2 week after starting treatment is as predictive as the study indicates at 6 weeks warrants further investigation.
Ähnliche Arbeiten
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 · 21.376 Zit.
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
2016 · 15.798 Zit.
The 2007 WHO Classification of Tumours of the Central Nervous System
2007 · 13.907 Zit.
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010
2013 · 12.093 Zit.
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
2021 · 11.333 Zit.